Membrane transport simulator — characterizing an individual patient's peritoneal membrane to guide peritoneal dialysis prescription
Every patient's peritoneum behaves like a slightly different dialysis filter. Surface area, capillary density, and effective pore distribution vary from person to person and can change over years on therapy. The peritoneal equilibration test (PET) exists to measure this individual variability directly, rather than assuming a "one prescription fits all" approach — turning an invisible physiological property into an actionable, reproducible number.
The peritoneal membrane is not a passive plastic sheet — it is a living, vascularized tissue. Three anatomical layers separate peritoneal capillary blood from the dialysate sitting in the peritoneal cavity: the capillary endothelium, the interstitium, and the mesothelium. Each layer contributes resistance to solute and water movement, and the effective peritoneal surface area in contact with dialysate — determined largely by perfused capillary density — differs substantially between individuals.
A patient with a highly vascularized, permeable membrane will equilibrate small solutes (like creatinine and urea) with blood very quickly. A patient with a less permeable membrane will equilibrate much more slowly. If every patient were given an identical dwell schedule, the fast-equilibrating patient would gain little additional clearance from a long dwell (and would lose ultrafiltration to glucose absorption), while the slow-equilibrating patient would be under-dialyzed on a short-dwell regimen. The PET converts this invisible biological difference into a measurable, actionable classification.
Membrane transport status is not fixed for life — peritonitis episodes, long-term glucose exposure, and time on peritoneal dialysis can shift a patient toward higher transport over the years, which is why the test may be repeated periodically.
The PET result feeds directly into two intertwined clinical decisions:
1. Modality selection — whether continuous ambulatory peritoneal dialysis (CAPD, long manual dwells) or automated peritoneal dialysis (APD, short cycler-driven dwells overnight) is more likely to achieve adequate clearance and fluid balance for that specific patient.
2. Prescription design — dwell volume, dwell duration, number of exchanges per day, and dextrose/glucose concentration of the dialysate, all tuned to the patient's measured transport rate rather than a population average.
Without this individualized characterization, patients risk two failure modes: under-clearance of uremic solutes (inadequate dialysis) or progressive fluid overload from lost ultrafiltration capacity — both of which are avoidable once the membrane's transport behavior is known.
For the PET result to mean anything comparable across patients, clinics, and time, it must be measured the same way every time. The test follows a fixed protocol: a defined dialysate dwell of standard volume and dextrose concentration, with dialysate and blood samples drawn at pre-specified timepoints during that dwell. This standardization is what allows a single number — the D/P creatinine ratio — to be placed reliably onto a reference transport curve.
A standardized PET generally proceeds as follows:
• Prior dwell drained completely — the abdomen starts empty so the test dwell is not contaminated by residual dialysate. • A measured volume of dextrose-containing dialysate (a fixed concentration, most often 2.5% dextrose) is instilled over a short, timed period. • Dialysate samples are drawn at defined timepoints during the dwell — commonly at the start, partway through, and at the end of the dwell. • A blood sample is drawn during the dwell to measure plasma creatinine, providing the denominator for the ratio. • At the end of the dwell, the dialysate is drained completely and its volume measured — this drained volume is used to assess net ultrafiltration for that dwell.
Every step — fill rate, dwell duration, sample timing, drain technique — is protocolized so that the resulting numbers are comparable to the reference population the classification bands were derived from.
Solute equilibration is time-dependent: dialysate-to-plasma ratios rise continuously throughout a dwell as diffusion proceeds toward equilibrium, and ultrafiltration volume rises then can fall as glucose is absorbed and its osmotic pull fades. If the dwell time, fill volume, or dextrose strength were left to vary between tests, two patients with identical membranes could produce very different raw numbers purely because of protocol differences — making classification meaningless.
By fixing these variables, the observed D/P creatinine ratio at the standard sampling timepoint becomes attributable almost entirely to the patient's intrinsic membrane transport rate. This is what allows it to be plotted directly against reference transport curves built from large populations of previously tested patients, and to be classified into one of four transport categories with confidence.
At the heart of the PET is a single, elegant ratio: how much creatinine has diffused into the dialysate compared to how much remains in the blood, at the standardized sampling timepoint. Creatinine is chosen as the reference solute because it is a small, freely diffusible molecule that behaves predictably across the membrane, making it an excellent proxy for overall small-solute transport behavior.
At the start of a dwell, dialysate creatinine concentration is essentially zero and plasma creatinine concentration is whatever the patient's baseline is — so D/P starts near 0. As the dwell progresses, creatinine diffuses down its concentration gradient from the peritoneal capillary blood, across the membrane, into the dialysate. Over a long enough dwell, dialysate and plasma concentrations would approach each other and D/P would approach 1.0 (full equilibration).
The D/P Cr ratio measured at the standardized sampling timepoint captures where the patient sits along that diffusion curve at that moment. A higher ratio means more creatinine crossed the membrane in the same amount of time — that is, faster diffusive transport. A lower ratio means the membrane is a slower conduit for solute movement, so less equilibration has occurred by the same timepoint.
The measured D/P Cr value is compared against reference bands built from population data, sorting patients into four transport categories: low, low-average, high-average, and high transporters. Because the underlying biological property — diffusive permeability — exists on a continuum, the boundaries between categories are population-derived cut points rather than sharp biological transitions, but they have proven clinically useful for guiding prescription decisions for decades.
Importantly, the ratio is only meaningful in the context of the standardized protocol described in Stage 2 — the same D/P value measured at a different dwell time or with a different dialysate strength would not be comparable to the reference bands.
Once the D/P creatinine ratio is measured, patients are placed along a spectrum of four transport categories: low, low-average, high-average, and high transporters. This is not simply a label — each category carries distinct, clinically important implications for how quickly solutes clear and how well ultrafiltration is sustained across a dwell.
Low transporters have the slowest diffusive equilibration — solutes cross the membrane gradually, so dialysate concentrations stay lower relative to plasma even by the end of a standard dwell. The upside is that the osmotic (glucose) gradient driving ultrafiltration is preserved longer, so these patients tend to retain good ultrafiltration across long dwells.
High transporters sit at the opposite end: solutes equilibrate rapidly, so a high fraction of achievable diffusion happens early in the dwell. But the same rapid membrane permeability applies to glucose — it is absorbed from the dialysate into the blood quickly, collapsing the osmotic gradient that drives fluid removal. The practical consequence is that high transporters can lose ultrafiltration capacity, and even reabsorb fluid, if dwells are left too long.
Low-average and high-average transporters fall between these extremes, generally showing the most balanced combination of adequate solute clearance and preserved ultrafiltration across a range of dwell times — which is one reason this middle range is the most common in PD populations.
The classification captures an intrinsic trade-off: transport rate governs both how fast solutes clear and how fast the osmotic ultrafiltration gradient dissipates. There is no category that is simply "better" — each has an optimal dwell strategy:
• Low transporters need long dwells to accumulate meaningful diffusive clearance, since equilibration is slow; short dwells under-clear solutes for these patients. • High transporters achieve most of their diffusive clearance early, so extending the dwell further mainly serves to reabsorb fluid via glucose depletion, without adding much additional solute clearance.
Recognizing where a patient sits on this spectrum is what allows the prescription to be tailored — rather than applying long dwells to everyone (harming high transporters' fluid balance) or short dwells to everyone (under-dialyzing low transporters).
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Low | |||
| Low-average | |||
| High-average | |||
| High |
The PET result is not an academic curiosity — it is directly translated into modality and dwell-schedule decisions. High transporters often do better with shorter, more frequent dwells, favoring cycler-based automated peritoneal dialysis (APD). Low transporters may need longer dwells for adequate solute clearance, favoring continuous ambulatory peritoneal dialysis (CAPD). The test result is the single most influential input into this individualization.
Because high transporters equilibrate solutes quickly but also lose the osmotic ultrafiltration gradient quickly, the ideal strategy is to drain and refill the dialysate before glucose absorption erodes the gradient — capturing the early, efficient window of both diffusion and ultrafiltration repeatedly rather than leaving one dwell in place for hours. This favors automated peritoneal dialysis, where a cycler performs multiple short exchanges overnight while the patient sleeps, refreshing the osmotic gradient frequently and avoiding the long, fluid-reabsorbing dwells that would otherwise occur with a manual CAPD schedule.
Low transporters equilibrate solutes slowly, so a short dwell simply does not give diffusion enough time to move a meaningful amount of solute across the membrane — clearance would be inadequate. These patients benefit from longer dwells that allow diffusion to proceed further toward equilibrium, which is naturally compatible with continuous ambulatory peritoneal dialysis, where dwells of several hours (including an extended overnight dwell) are standard. Because ultrafiltration is well preserved even over long dwells in this group, extending dwell time does not carry the same fluid-reabsorption penalty seen in high transporters.
The PET is one input among several — residual kidney function, patient lifestyle, dexterity, and comorbidities also shape the final modality decision. But among physiological measurements, transport category is the most direct, reproducible guide to how a given patient's membrane will respond to different dwell strategies.
Because peritoneal membrane transport can shift over years on dialysis — often trending toward faster transport after recurrent peritonitis episodes or prolonged high-glucose dialysate exposure — the PET is not a one-time test. Periodic re-testing allows the prescription to be re-tuned as the membrane changes, catching a drift toward high transport (and declining ultrafiltration) before it manifests clinically as fluid overload, or confirming that a stable low-transport patient continues to be well served by their long-dwell CAPD schedule.